Skye Bioscience (SKYE) Current Deferred Revenue (2016 - 2017)

Skye Bioscience (SKYE) posted quarterly Current Deferred Revenue of $817.0 for Q2 2017, down 49.97% quarter-over-quarter from $1633.0 in Q1 2017.

Skye Bioscience (SKYE) Current Deferred Revenue (2016 - 2017) Analysis & Trends

Skye Bioscience (SKYE) has reported Current Deferred Revenue for 2 consecutive years, with $817.0 the latest figure, recorded in Q2 2017.

In Q2 2017, Current Deferred Revenue changed N/A year-over-year to $817.0; the TTM figure through Jun 2017 stood at $817.0 (changed N/A YoY), while the FY2016 annual figure was $2450.0, changed N/A from the prior year.
Current Deferred Revenue fell to $817.0 in Q2 2017 per SKYE's latest filing, from $1633.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $2450.0 in Q4 2016 and bottomed at $817.0 in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.95 Bn	132.10 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn
3	Argenx Se	65.71 Bn	60.52 Bn	1.37 Bn
4	Moderna	60.45 Bn	55.31 Bn	52.00 Mn
5	BeOne Medicines	42.24 Bn	37.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn
7	BioNTech SE	28.64 Bn	10.25 Bn	668.28 Mn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn
9	Royalty Pharma	27.26 Bn	26.42 Bn	-
10	Skye Bioscience	10.75 Mn	10.75 Mn	-

Download Data